ReviewInternational journal of molecular sciences2022
Perspectives for the Use of Fucoidans in Clinical Oncology.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Plant- and Algae-Derived Compounds Enhance the Anticancer Activity of Doxorubicin in Colorectal Cancer Cell Lines.Molecules (Basel, Switzerland) · 2026Article
- Fucoidans as multifunctional marine polysaccharide platforms: From nutritional supplements to advanced drug delivery for cancer therapy.International journal of pharmaceutics: X · 2026Review
- Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.Biomedicines · 2026Review
- Marine nutraceuticals and their role in modulating diabetes-induced carcinogenesis.Diabetology & metabolic syndrome · 2026Review
- Fucoidan induces ferroptosis in colorectal cancer cells by regulating the SLC7A11/GPX4 signaling pathway and modulating metabolic pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Bioactive compounds from marine algae in pancreatic cancer therapy: mechanistic insights into fucoidan and phlorotannins: a review.Medical oncology (Northwood, London, England) · 2025Review
- Fucoidan-based Nanomedicine for Hearing Loss: Emerging Roles as Carrier and Therapeutic Agent.Pharmaceutical research · 2025Review
- Implantable Bioresorbable Scaffold with Fucosylated Chondroitin Sulfate as a Promising Device for Delayed Stimulation of Hematopoiesis.Marine drugs · 2025Article
- Herbal Medicine: Enhancing the Anticancer Potential of Natural Products in Hepatocellular Carcinoma Therapy Through Advanced Drug Delivery Systems.Pharmaceutics · 2025Review
- Structure of a Sulfated Capsular Polysaccharide from the Marine BacteriumMarine drugs · 2025Article
- Anticancer Activity of Plant Tocotrienols, Fucoxanthin, Fucoidan, and Polyphenols in Dietary Supplements.Nutrients · 2024Article
- Structure and Biosynthetic Gene Cluster of Sulfated Capsular Polysaccharide from the Marine BacteriumInternational journal of molecular sciences · 2024Article
- Marine-Derived Fucose-Containing Carbohydrates: Review of Sources, Structure, and Beneficial Effects on Gastrointestinal Health.Foods (Basel, Switzerland) · 2024Review
- Anticancer Mechanism ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Hydrogel systems for spatiotemporal controlled delivery of immunomodulators: engineering the tumor immune microenvironment for enhanced cancer immunotherapy.Frontiers in cell and developmental biology · 2024Review
- Stereocontrolled Synthesis and Conformational Analysis of a Series of Disaccharides α,β-d-GlcA-(1→3)-α-L-Fuc.Molecules (Basel, Switzerland) · 2023Article
- Article
- Combined Radiomodifying Effect of Fucoidan from the Brown AlgaBiomolecules · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Fucoidans are natural sulfated polysaccharides that have a wide range of biological functions and are regarded as promising antitumor agents. The activity of various fucoidans and their derivatives has been demonstrated in vitro on tumor cells of different histogenesis and in experiments on mice with grafted tumors. However, these experimental models showed low levels of antitumor activity and clinical trials did not prove that this class of compounds could serve as antitumor drugs. Nevertheless, the anti-inflammatory, antiangiogenic, immunostimulating, and anticoagulant properties of fucoidans, as well as their ability to stimulate hematopoiesis during cytostatic-based antitumor therapy, suggest that effective fucoidan-based drugs could be designed for the supportive care and symptomatic therapy of cancer patients. The use of fucoidans in cancer patients after chemotherapy and radiation therapy might promote the rapid improvement of hematopoiesis, while their anti-inflammatory, immunomodulatory, and anticoagulant effects have the potential to improve the quality of life of patients with advanced cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.